MicroRNA profile of poorly differentiated thyroid carcinomas: New diagnostic and prognostic insights

Journal of Molecular Endocrinology

Volumn 52, Issue 2, 2014, Pages 181-189

  Dettmer, Matthias S ^a,b   Perren, Aurel ^b   Moch, Holger ^c   Komminoth, Paul ^d   Nikiforov, Yuri E ^a   Nikiforova, Marina N ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Diagnosis; Follicular thyroid carcinoma; Mirna profiling; Papillary; Poorly differentiated carcinoma; Prognosis; Rcinoma; Thyroid cancer

Indexed keywords

MICRORNA; MICRORNA 125A 5P; MICRORNA 130B; MICRORNA 139 5P; MICRORNA 150; MICRORNA 15A 3P; MICRORNA 182; MICRORNA 183 3P; MICRORNA 193A 5P; MICRORNA 219 5P; MICRORNA 221; MICRORNA 222; MICRORNA 222 5P; MICRORNA 23B; MICRORNA 451; MICRORNA 455 3P; MICRORNA 885 5P; MICRORNA 886 3P; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; FEMALE; FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; UPREGULATION;

DIAGNOSIS; FOLLICULAR THYROID CARCINOMA; MIRNA PROFILING; PAPILLARY CARCINOMA; POORLY DIFFERENTIATED CARCINOMA; PROGNOSIS; THYROID CANCER;

CELL DIFFERENTIATION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; THYROID NEOPLASMS;

EID: 84897875416     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-13-0266     Document Type: Article

References (39)

1. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297. (doi:10.1016/S0092-8674(04)00045-5)
2. Carcangiu ML, Zampi G & Rosai J 1984 Poorly differentiated ("insular") thyroid carcinoma. A reinterpretation of Langhans' "wuchernde Struma". American Journal of Surgical Pathology 8 655-668. (doi:10.1097/ 00000478-198409000-00005)
3. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ & Scognamiglio T 2008 MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Modern Pathology 21 1139-1146. (doi:10.1038/modpathol.2008.105)
4. DeLellis R, Lloyd R, Heitz P & Eng C 2004 Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press.
5. Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, Komminoth P & Perren A 2011 Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? American Journal of Surgical Pathology 35 1866-1872. (doi:10.1097/PAS.0b013e31822cf962)
6. Dettmer M, Schmitt A, Steinert H, Moch H, Komminoth P & Perren A 2012 Poorly differentiated oncocytic thyroid carcinoma - diagnostic implications and outcome. Histopathology 60 1045-1051. (doi:10.1111/ j.1365-2559.2012.04188.x)
7. Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, Nikiforov YE & Nikiforova MN 2013a MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 98 E1-E7. (doi:10.1210/jc.2012-2694)
8. Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE & Nikiforova MN 2013b Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid 23 1383-1389. (doi:10.1089/thy.2012.0632)
9. Galasso M, Sandhu SK & Volinia S 2012 MicroRNA expression signatures in solid malignancies. Cancer Journal 18 238-243. (doi:10.1097/PPO. 0b013e318258b5f4)
10. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT et al. 2009 CMyc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458 762-765. (doi:10.1038/nature07823)
11. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S et al. 2005 The role of microRNA genes in papillary thyroid carcinoma. PNAS 102 19075-19080. (doi:10.1073/ pnas.0509603102)
12. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R et al. 2012 A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clinical Cancer Research 18 2032-2038. (doi:10.1158/1078-0432.CCR-11-2487)
13. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR et al. 2009 Therapeuticmicro RNA delivery suppresses tumorigenesisinamurine liver cancer model. Cell 137 1005-1017. (doi:10.1016/j.cell.2009.04.021)
14. Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov A et al. 2013 MIR-139-5p is a regulator of metastatic pathways in breast cancer. RNA 19 1767-1780. (doi:10.1261/rna.042143.113)
15. Lee RC, Feinbaum RL & Ambros V 1993 The C.elegansheterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 843-854. (doi:10.1016/0092-8674(93)9REF16Z10.1006/meth.2001.1262)
16. Leone V, D'Angelo D, Pallante P, Croce CM & Fusco A 2012 Thyrotropin regulates thyroid cell proliferation by up-regulating miR-23b and miR-29b that target SMAD3. Journal of Clinical Endocrinology and Metabolism 97 3292-301. (doi:10.1210/jc.2012-1349)
17. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(KDelta Delta C(T)) method. Methods 25 402-408. (doi:10.1006/meth.2001.1262)
18. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA et al. 2005 MicroRNA expression profiles classify human cancers. Nature 435 834-838. (doi:10.1038/ nature03702)
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M & Clark GM 2005 REporting recommendations for tumour MARKer prognostic studies (REMARK). European Journal of Cancer 41 1690-1696. (doi:10.1016/j.ejca.2005.03.032)
20. Menon MP & Khan A 2009 Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. Journal of Clinical Pathology 62 978-985. (doi:10.1136/jcp.2008.063909)
21. Nikiforov YEB, Paul W & Thompson LD 2009 Diagnostic Pathology and Molecular Genetics of the Thyroid. Philadelphia, PA, USA: Lippincott Williams & Wilkins (LWW).
22. Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE 2008 MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism 93 1600-1608. (doi:10.1210/jc.2007-2696)
23. Nikiforova MN, Chiosea SI & Nikiforov YE 2009 MicroRNA expression profiles in thyroid tumors. Endocrine Pathology 20 85-91. (doi:10.1007/ s12022-009-9069-z)
24. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 69 4885-4893. (doi:10.1158/ 0008-5472.CAN-09-0727)
25. Sakamoto A, Kasai N & Sugano H 1983 Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52 1849-1855. (doi:10.1002/1097-0142(19831115)52:10!1849::AID-CNCR2820521015O3.0.CO;2-X)
26. Schwertheim S, Sheu SY, Worm K, Grabellus F & Schmid KW 2009 Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Hormone and Metabolic Research 41 475-481. (doi:10.1055/s-0029-1215593)
27. Sheu SY, Grabellus F, Schwertheim S, Worm K, Broecker-Preuss M & Schmid KW 2010 Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. British Journal of Cancer 102 376-382. (doi:10.1038/sj.bjc.6605493)
28. Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, Couto JP, Prazeres H, Eloy C, Maximo V et al. 2011 Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Current Genomics 12 609-617. (doi:10.2174/138920211798120853)
29. Tallini G 2011 Poorly differentiated thyroid carcinoma. Are we there yet? Endocrine Pathology 22 190-194. (doi:10.1007/s12022-011-9176-5)
30. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA & Baloch ZW 2007 Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocrine Pathology 18 163-173. (doi:10.1007/s12022-007-0023-7)
31. Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y & Dahiya R 2013 MicroRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. British Journal of Cancer 108 1659-1667. (doi:10.1038/bjc.2013.125)
32. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM et al. 2007 MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer 14 791-798. (doi:10.1677/ERC-07-0129)
33. Volante M & Papotti M 2010 Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. Endocrine Pathology 21 1-6. (doi:10.1007/s12022-009-9100-4)
34. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M et al. 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology 31 1256-1264. (doi:10.1097/PAS. 0b013e3180309e6a)
35. Volante M, Rapa I & Papotti M 2008 Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocrine Pathology 19 150-155. (doi:10.1007/s12022-008-9040-4)
36. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M & Nikiforov YE 2009 RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. Journal of Clinical Endocrinology and Metabolism 94 4735-4741. (doi:10. 1210/jc.2009-1233)
37. Yamashita S, Ong J, Fagin JA & Melmed S 1986 Expression of the myc cellular proto-oncogene in human thyroid tissue. Journal of Clinical Endocrinology and Metabolism 63 1170-1173. (doi:10.1210/jcem-63-5-1170)
38. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE & Nikiforova MN 2011 MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Annals of Surgical Oncology 18 2035-2041. (doi:10.1245/s10434-011-1733-0)
39. Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H et al. 2013 MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Science 104 48-54. (doi:10.1111/ cas.12030)